Perrigo launches generic Solaraze gel
Perrigo has launched its generic Solaraze gel (diclofenac sodium gel 3%). The drug is indicated for the topical treatment of actinic keratoses.
The product had a market value of about $31 million for the 12 months ended September 2018, according to IQVIA.
“Bringing this new product to market is another illustration of the Rx team’s commitment to providing high quality, affordable Rx products that benefit patients in this important extended topical category,” Perrigo executive vice president and president of Rx pharmaceuticals Sharon Kochan said.
No comments found